ClinicalTrials.Veeva

Menu

Randomised Trial of Eutectic Mixture of Local Anaesthetics Cream and Oral Sucrose Solution for Venepuncture (VIEP)

A

Assistance Publique - Hôpitaux de Paris

Status and phase

Completed
Phase 4

Conditions

Pain

Treatments

Procedure: venepuncture

Study type

Interventional

Funder types

Other

Identifiers

NCT00470080
P060501

Details and patient eligibility

About

This randomized bicentric trial will investigate the efficacy of topical EMLA cream with oral sucrose solution compared to oral sucrose solution alone before venepuncture in preterm infants.

Full description

Venepuncture is a painful procedure commonly performed in premature infants. Nonpharmacological intervention (oral sucrose solution) can reduce neonatal pain. EMLA cream is an oil in water emulsion of an eutectic mixture of prilocaine and lignocaine; it is an local anesthetic cream. Very few reports have looked at the efficacy of EMLA in preterm infants.

This randomized bicentric trial will investigate the efficacy of topical EMLA cream with oral sucrose solution compared to oral sucrose solution alone before venepuncture in preterm infants.

Enrollment

80 patients

Sex

All

Ages

26 to 37 weeks old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • preterm infants (gestational age between 26 and 37 weeks)
  • programmed venepuncture
  • APGAR score (M5)≥ 7
  • enteral feeding
  • written parental consent

Exclusion criteria

  • infant requiring oxygen
  • analgesia or sedation or drugs causing methaemoglobinaemia
  • congenital porphyria
  • G6PD deficit
  • multi organ failure
  • convulsion
  • dermatosis

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

80 participants in 1 patient group

1
Experimental group
Description:
venepuncture
Treatment:
Procedure: venepuncture

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems